Hepatitis C Virus (HCV) - Epidemiology Forecast to 2030

Hepatitis C Virus (HCV) - Epidemiology Forecast to 2030

  • December 2020 •
  • 150 pages •
  • Report ID: 5993620 •
  • Format: PDF
‘Hepatitis C Virus (HCV) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted HCV epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Hepatitis C Virus (HCV) Understanding
Hepatitis C is a viral infection that causes liver inflammation and damage, sometimes leading to serious liver disorder. HCV spreads through contaminated blood or body fluids. High-risk settings include IDU and the transfusion of unscreened blood and blood products, unsafe injection practices, unsafe health care. Other possible but less well-characterized risk exposures include tattoos and piercings, needle sticks, and unsafe/traumatic sexual practices.

HCV can range from a mild illness lasting a few weeks to a serious, long-term illness. HCV can be acute or chronic. Acute HCV occurs within the first 6 months after the patient is exposed to HCV. Around 55-85% of infected persons develop chronic HCV infection. Chronic HCV can be a lifelong infection if left untreated. Chronic HCV can cause serious health problems, including liver damage, cirrhosis (scarring of the liver), liver cancer, and even death. Most patients with newly acquired HCV do not exhibit symptoms of infection within the first 6 months. For people who develop symptoms, they usually happen 2–12 weeks after exposure to the HCV and can include yellow skin or eyes, not wanting to eat, upset stomach, throwing up, stomach pain, fever, dark urine, light-colored stool, joint pain, and feeling tired. Most chronic hepatitis C people do not have any symptoms or have only general symptoms like chronic fatigue and depression.
HCV is distinguished into different categories called genotypes based on similar genes. HCV genotypes are 1 (1a and 1b), 2, 3, 4, 5, and 6. In the United States, genotypes 1, 2, and 3 are the most common. Genotype 3 is the second most common HCV subtype in the world and most hard to treat because of the rapid progression of liver disease, increased rates of steatosis (non-alcoholic fatty liver disease), and a higher risk for cancer (hepatocellular carcinoma).

Hepatitis C Virus (HCV) Diagnosis
HCV is diagnosed based on the patient’s medical history, a physical exam, and blood tests. If a viral infection is confirmed, doctors may suggest additional tests to check the condition of the liver.
Initial testing for the diagnosis of hepatitis C infection uses serologic assays that detect human antibodies generated as a response to HCV infection. Blood tests for HCV include screening tests for antibodies to the HCV virus, HCV RNA test, Genotype test, etc.
In Chronic HCV, doctors may recommend additional tests to find out how much liver damage the patient has, or to rule out other causes of liver disease. These tests may include blood tests, Imaging Tests (Transient elastography, Ultrasound, MRI, and CT Scan), and Liver function Tests (ALT, AST, ALP, and total bilirubin). If the liver is damaged due to inflammation, enzymes pass out of the liver into the bloodstream, making ALT and AST levels higher than normal. The doctor may also recommend a liver biopsy if blood tests or imaging studies suggest the patient might have a liver problem. A biopsy can determine the extent of scarring, or fibrosis, in a liver affected by viral hepatitis.

Epidemiology Perspective
The HCV epidemiology division provides insights about historical and current HCV patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
In the year 2017, the total prevalent case of HCV was 8,257,162 cases in the 7MM which are expected to grow during the study period, i.e., 2017–2030.
The disease epidemiology covered in the report provides historical as well as forecasted HCV epidemiology [segmented as Total Prevalent Cases of HCV, Total Diagnosed Cases of HCV, Gender-specific Cases of HCV, Age-specific Diagnosed Cases of HCV, Genotype-specific Diagnosed Cases of HCV, Diagnosed Cases of HCV by Impact on Liver, and Treated cases of HCV] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- HCV Epidemiology
Estimates show that the highest cases of HCV in the 7MM were in the United States, followed by Japan, Italy, Spain, France, Germany, and the United Kingdom in 2017.
• In the United States, the total number of prevalent cases of HCV was 3,251,471 cases in the year 2017 which are expected to grow during the study period, i.e., 2017–2030.
• In the year 2017, the total prevalent cases of HCV were 3,108,919 cases in EU-5 which are expected to grow during the study period, i.e., 2017–2030.
• In Japan, the total number of prevalent cases of HCV was 1,896,771 cases in the year 2017 which are expected to grow during the study period, i.e., 2017–2030.

Scope of the Report
• The HCV report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The HCV Report and Model provide an overview of the risk factors and global trends of HCV in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of HCV in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of HCV.
• The report provides the segmentation of the HCV epidemiology by total prevalent cases in the 7MM.
• The report provides the segmentation of the HCV epidemiology by total diagnosed cases in the 7MM.
• The report provides the segmentation of the HCV epidemiology by gender-specific cases in the 7MM.
• The report provides the segmentation of the HCV epidemiology by age-specific diagnosed cases in the 7MM.
• The report provides the segmentation of the HCV epidemiology by genotype-specific diagnosed cases in the 7MM.
• The report provides the segmentation of the HCV epidemiology by diagnosed cases by the impact on the liver in the 7MM.
• The report provides the segmentation of the HCV epidemiology by treated cases in the 7MM.

Report Highlights

• 11-Year Forecast of HCV epidemiology
• 7MM Coverage
• Total Prevalent Cases of HCV
• Total Diagnosed Cases of HCV
• Gender-specific Cases of HCV
• Age-specific Diagnosed Cases of HCV
• Genotype-specific Diagnosed Cases of HCV
• Diagnosed Cases of HCV by Impact on Liver
• Treated Cases of HCV
KOL-Views
We interview KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM concerning the patient population of HCV?
• What are the key findings of the HCV epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017–2030)?
• What would be the total number of patients of HCV across the 7MM during the study period (2017–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2017–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2017–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of HCV?

Reasons to buy
The HCV Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global HCV market
• Quantify patient populations in the global HCV market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the gender that presents the best opportunities for HCV therapeutics in each of the markets covered
• Understand the magnitude of HCV population by its severity
• The HCV epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The HCV Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 11-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2030
• In the year 2017, the total prevalent case of HCV was 8,257,162 cases in the 7MM, and the US, in 2017, accounted for 3,251,471 cases (the highest number), which will probably rise during the study period, i.e., 2017–2030.
• In the 7MM, the total gender-specific cases of HCV were 2,524,663 for males and 1,836,170 for females in the year 2017.
• In the 7MM, the age-specific diagnosed cases of HCV were 21,821, 157,489, 139,938, 310,234, 1,531,723, and 2,199,629 cases for the age group less than 18 years, 18–25 years, 26–35 years, 36–45 years, 46–55 years, and ?56 years, in 2017.
• In the 7MM, the genotype-specific diagnosed cases of HCV were 2,896,948, 688,014, 419,236, 226,662, 5,986, 18,881, and 103,661 cases for the Genotype 1, Genotype 2, Genotype 3, Genotype 4, Genotype 5, Genotype 6, and Mixed or other, in 2017.
• In 2017, there were nearly 872,167 decompensated liver cases, and 3,488,667 Compensated Liver cases in the 7MM.